Cat. No.: HY-16950A

(E/Z)-4-Hydroxytamoxifen

(Synonyms: Afimoxifene; 4-OHT)

3 Cited Publications

Customer Review

Based on 3 publication(s) in Google Scholar

(E/Z)-4-Hydroxytamoxifen (Afimoxifene) is a racemic compound of (Z)-4-Hydroxytamoxifen and (E)-4-Hydroxytamoxifen isomers. (E/Z)-4-Hydroxytamoxifen is a selective estrogen receptor modulator with mixed estrogenic and antiestrogenic activity, which is also an active metabolite of Tamoxifen (HY-13757A). (E/Z)-4-Hydroxytamoxifen is an agonist of the G protein-coupled estrogen receptor (GPER) with relatively low affinity (100-1000 nM). (E/Z)-4-Hydroxytamoxifen is promising for research of cyclical mastalgia, such as breast pain, tenderness, and nodularity.

For research use only. We do not sell to patients.

Purity: 99.62%
CAS No.: 68392-35-8
Formula: C₂₆H₂₉NO₂
Molecular Weight:387.51

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

(E/Z)-4-Hydroxytamoxifen Chemical Structure

CAS No.: 68392-35-8

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (3)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

Estrogen receptor

Human Endogenous Metabolite

All Estrogen Receptor/ERR Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
DU-145	EC₅₀	10 μM Compound: OH-TAM	Antiproliferative activity against human prostate, androgen receptor positive DU145 cells after 24 hrs by MTT assay Antiproliferative activity against human prostate, androgen receptor positive DU145 cells after 24 hrs by MTT assay	[PMID: 25198997]
DU-145	IC₅₀	15.3 μM Compound: 4OHT	Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 33965842]
HEK293	IC₅₀	0.07 μM Compound: 4-OHT	Antagonist activity at luciferase-fused ERalpha in human HEK293 cells expressing eYFP assessed as reduction of E2-induced estrogenic activity after 2 hrs by BRET assay Antagonist activity at luciferase-fused ERalpha in human HEK293 cells expressing eYFP assessed as reduction of E2-induced estrogenic activity after 2 hrs by BRET assay	[PMID: 26613635]
HEK293	IC₅₀	0.79 nM Compound: 4-OHT	Antagonist activity at FLAG-tagged ERalpha (unknown origin) expressed in HEK293 cells assessed as reduction in E2-induced ER-alpha-mediated transcriptional activity by luciferase reporter gene assay Antagonist activity at FLAG-tagged ERalpha (unknown origin) expressed in HEK293 cells assessed as reduction in E2-induced ER-alpha-mediated transcriptional activity by luciferase reporter gene assay	[PMID: 30940565]
Ishikawa	EC₅₀	11.5 μM Compound: OH-TAM	Antiproliferative activity against human ER-positive Ishikawa cells after 24 hrs by MTT assay Antiproliferative activity against human ER-positive Ishikawa cells after 24 hrs by MTT assay	[PMID: 25198997]
Ishikawa	IC₅₀	1.27 nM Compound: 4-OHT	Antiproliferative activity against human Ishikawa cells Antiproliferative activity against human Ishikawa cells	[PMID: 34710747]
Ishikawa	IC₅₀	3.57 μg/mL Compound: 4-Hydroxy-Tamoxifen	Inhibition of estradiol-induced proliferation in human Ishikawa cells after 72 hrs by Cell-titer-Glo assay Inhibition of estradiol-induced proliferation in human Ishikawa cells after 72 hrs by Cell-titer-Glo assay	[PMID: 28442256]
MCF-10A	IC₅₀	10 μM Compound: OH-TAM	Cytotoxicity against human MCF10A cells after 72 hrs by MTT assay Cytotoxicity against human MCF10A cells after 72 hrs by MTT assay	[PMID: 25198997]
MCF-10A	IC₅₀	21.5 μM Compound: 4OHT	Antiproliferative activity against human MCF-10A cells assessed as reduction in cell viability measured after 72 hrs by Cell Counting Kit-8 assay Antiproliferative activity against human MCF-10A cells assessed as reduction in cell viability measured after 72 hrs by Cell Counting Kit-8 assay	[PMID: 35611405]
MCF-10A	IC₅₀	21.5 μM Compound: 4-OHT	Cytotoxicity against human MCF-10A cells incubated for 72 hrs by CCK8 assay Cytotoxicity against human MCF-10A cells incubated for 72 hrs by CCK8 assay	[PMID: 37037140]
MCF-10A	IC₅₀	21.5 μM Compound: 4-OHT	Cytotoxicity against human MCF-10A cells assessed as inhibition of cell proliferation incubated for 72 hrs by CCK8 assay Cytotoxicity against human MCF-10A cells assessed as inhibition of cell proliferation incubated for 72 hrs by CCK8 assay	[PMID: 37584263]
MCF-10A	IC₅₀	21.51 μM Compound: 1b; 4-OHT	Cytotoxicity against human MCF-10A cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay Cytotoxicity against human MCF-10A cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 37161783]
MCF7	EC₅₀	3.5 nM Compound: 2a; 4OH-T	Antiproliferative activity against human MCF-7 cells incubated for 72 hrs by Cell-titer Glo assay Antiproliferative activity against human MCF-7 cells incubated for 72 hrs by Cell-titer Glo assay	[PMID: 34251202]
MCF7	EC₅₀	7.4 μM Compound: OH-TAM	Antiproliferative activity against human ER-negative MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human ER-negative MCF7 cells after 72 hrs by MTT assay	[PMID: 25198997]
MCF7	EC₅₀	8.8 μM Compound: OH-TAM	Antiproliferative activity against human ER-negative MCF7 cells after 24 hrs by MTT assay Antiproliferative activity against human ER-negative MCF7 cells after 24 hrs by MTT assay	[PMID: 25198997]
MCF7	IC₅₀	0.0033 μM Compound: 4-OHT	Antiproliferative activity against human MCF7 cells after 5 days by coulter counter analysis Antiproliferative activity against human MCF7 cells after 5 days by coulter counter analysis	[PMID: 27529700]
MCF7	IC₅₀	0.0034 μM Compound: 4-hydroxytamoxifen	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 5 days by Coulter counting method Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 5 days by Coulter counting method	[PMID: 28105283]
MCF7	IC₅₀	0.15 μM Compound: 4-OHT	Antiproliferative activity against human MCF7 cells treated for 48 hrs followed by refreshed every 96 hrs measured on day 10 by Lowry assay Antiproliferative activity against human MCF7 cells treated for 48 hrs followed by refreshed every 96 hrs measured on day 10 by Lowry assay	[PMID: 26613635]
MCF7	IC₅₀	0.67 μM Compound: 1b; 4-OHT	Antiproliferative activity against human tamoxifen-sensitive MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human tamoxifen-sensitive MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 37161783]
MCF7	IC₅₀	0.67 μM Compound: 4OHT	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by Cell Counting Kit-8 assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by Cell Counting Kit-8 assay	[PMID: 35611405]
MCF7	IC₅₀	0.67 μM Compound: 4-OHT	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against human MCF7 cells incubated for 72 hrs by CCK8 assay	[PMID: 37037140]
MCF7	IC₅₀	0.67 μM Compound: 4-OHT	Antiproliferative activity against ERalpha positive human MCF7 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CCK8 assay Antiproliferative activity against ERalpha positive human MCF7 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CCK8 assay	[PMID: 37584263]
MCF7	IC₅₀	0.95 μg/mL Compound: 4-Hydroxy-Tamoxifen	Inhibition of estradiol-induced proliferation in human MCF7 cells after 72 hrs by Cell-titer-Glo assay Inhibition of estradiol-induced proliferation in human MCF7 cells after 72 hrs by Cell-titer-Glo assay	[PMID: 28442256]
MCF7	IC₅₀	1.2 nM Compound: 4-OHT	Antiproliferative activity against human MCF7 cells Antiproliferative activity against human MCF7 cells	[PMID: 34710747]
MCF7	IC₅₀	10.1 μM Compound: 4-OHT	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay	[PMID: 30939353]
MCF7	IC₅₀	15.6 μM Compound: 4OHT	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 33965842]
MCF7	IC₅₀	17.5 μM Compound: 4-hydroxytamoxifen	Antiproliferative activity against human MCF7 cells measured after 72 hrs by sulforhodamine B assay Antiproliferative activity against human MCF7 cells measured after 72 hrs by sulforhodamine B assay	[PMID: 31465222]
MCF7	IC₅₀	20 μM Compound: 4-hydroxytamoxifen	Cytotoxicity against tamoxifen-resistant human MCF7 cells assessed as reduction in cell viability after 5 days by Coulter counting method Cytotoxicity against tamoxifen-resistant human MCF7 cells assessed as reduction in cell viability after 5 days by Coulter counting method	[PMID: 28105283]
MCF7	IC₅₀	22 μM Compound: 4-OHT	Antiproliferative activity against human tamoxifen-resistant MCF7 cells after 5 days by coulter counter analysis Antiproliferative activity against human tamoxifen-resistant MCF7 cells after 5 days by coulter counter analysis	[PMID: 27529700]
MCF7	IC₅₀	9.5 μM Compound: 4OHT	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 30053783]
MCF7	IC₅₀	9.5 μM Compound: 4-OHT	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 32283297]
MCF7	IC₅₀	9.9 nM Compound: 2	Antiproliferative activity against human MCF7 cells after 6 days in presence of estradiol by CellTiter-Glo assay Antiproliferative activity against human MCF7 cells after 6 days in presence of estradiol by CellTiter-Glo assay	[PMID: 29562737]
MDA-MB-231	EC₅₀	7.8 μM Compound: OH-TAM	Antiproliferative activity against human ER-positive MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human ER-positive MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 25198997]
MDA-MB-231	EC₅₀	8 μM Compound: OH-TAM	Antiproliferative activity against human ER-positive MDA-MB-231 cells after 24 hrs by MTT assay Antiproliferative activity against human ER-positive MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 25198997]
MDA-MB-231	IC₅₀	17.25 μM Compound: 4-OHT	Antiproliferative activity against ERalpha negative human MDA-MB-231 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CCK8 assay Antiproliferative activity against ERalpha negative human MDA-MB-231 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CCK8 assay	[PMID: 37584263]
MDA-MB-231	IC₅₀	18.43 μM Compound: 1b; 4-OHT	Antiproliferative activity against triple negative human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against triple negative human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 37161783]
MDA-MB-231	IC₅₀	18.43 μM Compound: 4OHT	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 72 hrs by Cell Counting Kit-8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 72 hrs by Cell Counting Kit-8 assay	[PMID: 35611405]
MDA-MB-231	IC₅₀	36.76 nM Compound: 4-OHT	Antiproliferative activity against human MDA-MB-231 cells Antiproliferative activity against human MDA-MB-231 cells	[PMID: 34710747]
MDA-MB-231	IC₅₀	6.51 μg/mL Compound: 4-Hydroxy-Tamoxifen	Inhibition of estradiol-induced proliferation in human MDA-MB-231 cells after 72 hrs by Cell-titer-Glo assay Inhibition of estradiol-induced proliferation in human MDA-MB-231 cells after 72 hrs by Cell-titer-Glo assay	[PMID: 28442256]
MRC5	IC₅₀	>100 nM Compound: 4-OHT	Antiproliferative activity against human MRC5 cells Antiproliferative activity against human MRC5 cells	[PMID: 34710747]
T47D	IC₅₀	0.01 μM Compound: 4-OHT	Antagonist activity at ERalpha in human T47D-KBLuc cells assessed as inhibition of E2-induced transcriptional activity by luciferase reporter gene assay Antagonist activity at ERalpha in human T47D-KBLuc cells assessed as inhibition of E2-induced transcriptional activity by luciferase reporter gene assay	[PMID: 26613635]
T47D	IC₅₀	0.024 μM Compound: 4-OHT	Antiproliferative activity against human T47D cells after 5 days by coulter counter analysis Antiproliferative activity against human T47D cells after 5 days by coulter counter analysis	[PMID: 27529700]
T47D	IC₅₀	0.54 μM Compound: 4-OHT	Antiproliferative activity against human tamoxifen-resistant T47D cells over-expressing PKC-alpha after 5 days by coulter counter analysis Antiproliferative activity against human tamoxifen-resistant T47D cells over-expressing PKC-alpha after 5 days by coulter counter analysis	[PMID: 27529700]
T47D	IC₅₀	1.95 μM Compound: 1b; 4-OHT	Antiproliferative activity against human T47D cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human T47D cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 37161783]
T47D	IC₅₀	1.95 μM Compound: 4-OHT	Antiproliferative activity against ERalpha positive human T47D cells assessed as inhibition of cell proliferation incubated for 72 hrs by CCK8 assay Antiproliferative activity against ERalpha positive human T47D cells assessed as inhibition of cell proliferation incubated for 72 hrs by CCK8 assay	[PMID: 37584263]
T47D	IC₅₀	11.59 μM Compound: 1b; 4-OHT	Antiproliferative activity against human T47D cells harboring ERalpha D538G mutant assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human T47D cells harboring ERalpha D538G mutant assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 37161783]
T47D	IC₅₀	8.9 μM Compound: 4-OHT	Antiproliferative activity against human T47D cells harboring ERalpha Y537S mutant assessed as inhibition of cell proliferation incubated for 72 hrs by CCK8 assay Antiproliferative activity against human T47D cells harboring ERalpha Y537S mutant assessed as inhibition of cell proliferation incubated for 72 hrs by CCK8 assay	[PMID: 37584263]
T47D	IC₅₀	9.13 μM Compound: 4-OHT	Antiproliferative activity against human T47D cells harboring ERalpha D538G mutant assessed as inhibition of cell proliferation incubated for 72 hrs by CCK8 assay Antiproliferative activity against human T47D cells harboring ERalpha D538G mutant assessed as inhibition of cell proliferation incubated for 72 hrs by CCK8 assay	[PMID: 37584263]
T47D	IC₅₀	9.89 μM Compound: 1b; 4-OHT	Antiproliferative activity against human T47D cells harboring ERalpha Y537S mutant assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human T47D cells harboring ERalpha Y537S mutant assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 37161783]
Vero	IC₅₀	15.1 μM Compound: 4OHT	Antiproliferative activity against African green monkey Vero cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against African green monkey Vero cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 33965842]

In Vitro

(E/Z)-4-Hydroxytamoxifen (10 μM, 0-90 min) oxidized by CYP2D6 represents a minor route of Tamoxifen metabolism, and then is converted to 3,4- dihydroxytamoxifen and Endoxifen (HY-18719E)^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

(E/Z)-4-Hydroxytamoxifen (20.9 mg/kg, gavage or i.p., daily for 7 days) reduces the body weight and induces a significant increase in ethoxyresorufin O-deethylase activity in rats^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Sprague-Dawley rats^[3]
Dosage:

20.9 mg/kg
Administration:

gavage or i.p., daily for 7 days
Result:

Caused a significant reduction in body weight and induced a significant increase in ethoxyresorufin O-deethylase activity in rats.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 68392-35-8
Appearance Solid
Molecular Weight 387.51
Formula C₂₆H₂₉NO₂
Color White to off-white
SMILES

OC1=CC=C(/C(C2=CC=C(OCCN(C)C)C=C2)=C(C3=CC=CC=C3)\CC)C=C1
Synonyms

Afimoxifene; 4-OHT
Structure Classification
- Alkaloids
- Other Alkaloids
- Phenols
- Monophenols
Initial Source
- Endogenous metabolite
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (3)

All IPCell Proliferation/Viability AssayWBRT-PCR

Sort by:

Journal Impact Factor

Drug Resist Updat

ZBP1 antagonizes MRE11-mediated DNA end resection and confers synthetic lethality to PARP inhibition in ovarian cancer. [Abstract]

2026 Jan:84:101319. PMID: 41192279

(E/Z)-4-Hydroxytamoxifen purchased from MedChemExpress. Usage Cited in: Drug Resist Updat. 2026 Jan:84:101319. [Abstract]

Representative quantification of ZBP1 recruitment to the HR-DSB locus near the AsiSI cleavage site in AsiSI-ER-U2OS cells treated with or without 4-OHT(300 nM, 4 h).
Sci Immunol

Innate lymphoid cells originate from fetal liver-derived tissue-resident progenitors. [Abstract]

2025 Jul 11;10(109):eadu7962. PMID: 40644510
Oncol Lett

AGR3 promotes estrogen receptor-positive breast cancer cell proliferation in an estrogen-dependent manner. [Abstract]

2020 Aug;20(2):1441-1451. PMID: 32724387

(E/Z)-4-Hydroxytamoxifen purchased from MedChemExpress. Usage Cited in: Oncol Lett. 2020 Aug;20(2):1441-1451. [Abstract]

The viability of T47D cells treated with 0-10 µmol 4-OH Tam was detected using the Cell Counting Kit-8 assay.

(E/Z)-4-Hydroxytamoxifen purchased from MedChemExpress. Usage Cited in: Oncol Lett. 2020 Aug;20(2):1441-1451. [Abstract]

The protein levels of AGR3 and ER in T47D cells treated with 0, 2, 4, 6, 8 and 10 µmol 4-OH Tam for 24 h were detected by western blotting.

(E/Z)-4-Hydroxytamoxifen purchased from MedChemExpress. Usage Cited in: Oncol Lett. 2020 Aug;20(2):1441-1451. [Abstract]

RNA expression levels of ESR1 were detected in T47D cells after the addition of different concentrations of 4‑OH Tam for 24 h.

Solvent & Solubility

In Vitro:

DMSO : 83.33 mg/mL (215.04 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.5806 mL

12.9029 mL

25.8058 mL

5 mM

0.5161 mL

2.5806 mL

5.1612 mL

10 mM

0.2581 mL

1.2903 mL

2.5806 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (5.37 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (5.37 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (604 KB)
- English - EN (604 KB)
- Français - FR (604 KB)
- Deutsch - DE (604 KB)
- Norwegian - NO (604 KB)
- Español - ES (604 KB)
- Swedish - SV (604 KB)
- Italian - IT (604 KB)
- Korean - KR (604 KB)
- Portuguese - PT (604 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Mansel R, et al. A phase II trial of Afimoxifene (4-hydroxytamoxifen gel) for cyclical mastalgia in premenopausal women. Breast Cancer Res Treat. 2007 Dec;106(3):389-97. [Content Brief]

[2]. Desta Z, et al. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75. [Content Brief]

[3]. Gamboa da Costa G, et al. DNA adduct formation and mutant induction in Sprague-Dawley rats treated with tamoxifen and its derivatives. Carcinogenesis. 2001 Aug;22(8):1307-15. [Content Brief]

[4]. Prossnitz ER, et al. International Union of Basic and Clinical Pharmacology. XCVII. G Protein-Coupled Estrogen Receptor and Its Pharmacologic Modulators. Pharmacol Rev. 2015 Jul;67(3):505-40. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.5806 mL	12.9029 mL	25.8058 mL	64.5145 mL
	5 mM	0.5161 mL	2.5806 mL	5.1612 mL	12.9029 mL
	10 mM	0.2581 mL	1.2903 mL	2.5806 mL	6.4514 mL
	15 mM	0.1720 mL	0.8602 mL	1.7204 mL	4.3010 mL
	20 mM	0.1290 mL	0.6451 mL	1.2903 mL	3.2257 mL
	25 mM	0.1032 mL	0.5161 mL	1.0322 mL	2.5806 mL
	30 mM	0.0860 mL	0.4301 mL	0.8602 mL	2.1505 mL
	40 mM	0.0645 mL	0.3226 mL	0.6451 mL	1.6129 mL
	50 mM	0.0516 mL	0.2581 mL	0.5161 mL	1.2903 mL
	60 mM	0.0430 mL	0.2150 mL	0.4301 mL	1.0752 mL
	80 mM	0.0323 mL	0.1613 mL	0.3226 mL	0.8064 mL
	100 mM	0.0258 mL	0.1290 mL	0.2581 mL	0.6451 mL

Keywords

(E/Z)-4-Hydroxytamoxifen

3 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

(E/Z)-4-Hydroxytamoxifen

Bioactive Compound Library Max

Bioactive Compound Library

GPCR/G Protein Compound Library

Metabolism/Protease Compound Library

Natural Product Library

Anti-Cancer Compound Library

Clinical Compound Library

Drug Repurposing Compound Library

Phenols Library

Alkaloids Library

Drug Metabolite Library

Anti-Cancer Natural Product Library

Human Metabolite Library

Nuclear Receptor Compound Library

Membrane Receptor-targeted Compound Library

Animal-Sourced Natural Product Library

Highly Selective Activators Library

Multi-Target Compound Library

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Natural Product and Natural Product-Like Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Metabolite Library

RNA Binding Bioactive Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) (E/Z)-4-Hydroxytamoxifen

All Estrogen Receptor/ERR Isoforms

Biological Activity

Chemical Information

Publications (3)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

(E/Z)-4-Hydroxytamoxifen

Bioactive Compound Library Max

Bioactive Compound Library

GPCR/G Protein Compound Library

Metabolism/Protease Compound Library

Natural Product Library

Anti-Cancer Compound Library

Clinical Compound Library

Drug Repurposing Compound Library

Phenols Library

Alkaloids Library

Drug Metabolite Library

Anti-Cancer Natural Product Library

Human Metabolite Library

Nuclear Receptor Compound Library

Membrane Receptor-targeted Compound Library

Animal-Sourced Natural Product Library

Highly Selective Activators Library

Multi-Target Compound Library

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Natural Product and Natural Product-Like Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Metabolite Library

RNA Binding Bioactive Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) (E/Z)-4-Hydroxytamoxifen

All Estrogen Receptor/ERR Isoforms

Biological Activity

Chemical Information

Publications (3)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

(E/Z)-4-Hydroxytamoxifen Related Classifications

HY-16950A Related Classifications